TOP ALLIANCES BY TOTAL PAID UPFRONT, BY QUARTER

Upfront payments are defined as the total of any licensing fees and equity purchases upon deal signing.

Q4/2000
Date Alliance $ Value (in millions)
10/00 Debiotech to develop insulin pump for Inverness Medical 10.0

Q3/2000
Date Alliance $ Value (in millions)
8/00 Roche puts $40mm into TriPath Imaging 40.0
7/00 BMS, 3-Dimensional Pharma in drug discovery collaboration 23.5
8/00 Bayer, PPL Therapeutics to develop AAT-deficiency drug 15.0
9/00 Baxter Healthcare, Peptide Therapeutics develop vaccines 14.7
8/00 Amgen, HealthCite in software alliance 10.0

Q2/2000
Date Alliance $ Value (in millions)
6/00 Aventis, Millennium sign $450mm anti-inflammatory drug deal 150.0
4/00 Guidant, Cordis sign broad alliance 125.0
6/00 AHP's Wyeth-Ayerst in $150mm co-promotion with King 75.0
5/00 Tularik and Japan Tobacco sign their third alliance 25.0
6/00 RP Scherer licenses APS's technologies; buys manuf. plant 25.0
6/00 AHP's Wyeth-Ayerst in $150mm co-promotion with King 25.0

Q1/2000
Date Alliance $ Value (in millions)
3/00 CAT, Human Genome Sciences in $67mm antibody collaboration 67.0
2/00 Actelion, Genentech co-promote tezosentan in US 15.0
1/00 Glaxo and NeuroSearch to co-develop antidepressant 10.0
1/00 Xoma licenses Baxter Healthcare rights to Neuprex 9.5
2/00 Lion, Tripos ally to develop drug discovery platform 9.0

More information:
http://www.windhoverinfo.com/contents/weborig/RxUFbyQ.htm